Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add filters








Year range
1.
Acta Academiae Medicinae Sinicae ; (6): 607-610, 2016.
Article in English | WPRIM | ID: wpr-277932

ABSTRACT

Implant-based breast reconstruction is the most common choice in breast cancer patients. Recently,the acellular dermal matrix (ADM) technique has been widely used in implant-based breast reconstruction in the western countries. This article briefly reviews the biological characteristics,history,types,surgical techniques,and postoperative complications of ADM.


Subject(s)
Female , Humans , Acellular Dermis , Breast Implantation , Breast Implants , Breast Neoplasms , General Surgery , Mastectomy , Postoperative Complications
2.
Journal of Southern Medical University ; (12): 1047-1050, 2011.
Article in Chinese | WPRIM | ID: wpr-235200

ABSTRACT

<p><b>OBJECTIVE</b>To evaluate the value of cardiac troponin I (CTnI) measurement in predicting anthracycline-induced cardiotoxicity in patients with breast cancer.</p><p><b>METHODS</b>This study was conducted among 186 breast cancer patients receiving anthracycline-based chemotherapy. Serum cTnI concentrations before and after each cycle of the chemotherapy and the left ventricular ejection fraction (LVEF) before and at the 2nd, 4th and 6th months of the treatment were recorded. According to serum cTnI concentration, the patients were divided into CTnI+ group (with serum CTnI concentration of no less than 0.1 ng/ml, n=60) and CTnI- (<0.1 ng/ml) group (n=126).</p><p><b>RESULTS</b>No patients in this series experienced cardiac heart failure (CHF). The number of patients with a LVEF reduction by over 10% from the baseline was 16 (26.7%) in CTnI+ group, as compared to 7 (5.6%) in CTnI- group, showing a significant difference between the two groups (P<0.01).</p><p><b>CONCLUSION</b>CTnI can be a useful marker for early prediction of anthracycline-induced cardiotoxicity in patients with breast cancer.</p>


Subject(s)
Adult , Aged , Female , Humans , Middle Aged , Young Adult , Anthracyclines , Therapeutic Uses , Antibiotics, Antineoplastic , Therapeutic Uses , Biomarkers , Blood , Breast Neoplasms , Drug Therapy , Cardiotoxins , Myocardium , Metabolism , Troponin I , Blood
SELECTION OF CITATIONS
SEARCH DETAIL